

REIMAGINING EYE CARE

Alcon is the global leader in eye care. As a division of Novartis, we discover new ways to enhance sight and improve people's lives. We have done this successfully for over 70 years, through innovative products, partnerships with eye care professionals and programs that create greater access to quality eye care.



WHO WE ARE & WHY WE EXIST

Sight is arguably our most important sense, and data shows that people describe losing eyesight as potentially having the greatest impact on their day-to-day life.¹

Alcon began as a small ophthalmic pharmaceutical shop in Fort Worth, Texas. Through breakthrough innovations, strategic acquisitions and partnerships, and a deep-rooted commitment to partnering with and serving eye care professionals, we've grown into the global leader in eye care.

Our products touch the lives of millions of people each year living with conditions like cataracts, glaucoma, retinal diseases, dry eye, and refractive errors. We offer the most complete line of ophthalmic surgical devices, dry eye and ocular health portfolio, as well as a differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

QUICK FACTS



Incorporated in 1947



Operations in
74 countries



20,000 associates



Serving patients in
140 countries



REIMAGINING **EYE CARE** TO ADDRESS GROWING PATIENT NEEDS

As the population grows and ages, the need for quality eye care is expanding and evolving. And in many parts of the world, people do not have access to quality eye care.



20 million are blind from **cataracts**



1.7 billion have **presbyopia**



153 million have uncorrected **refractive errors**



93 million have **diabetic retinopathy**



340 million suffer with **dry eye**²

Reimagining eye care means we are at the **forefront of innovation**, and **partnering** with eye care professionals and organizations to **bring the gift of sight to more people around the world**.



LEADING IN INNOVATION

Our team of world-class scientists and engineers works every day to identify and develop technologies that deliver better visual outcomes and address unmet patient needs. We're focused on continuously improving the options that exist today while also exploring new disease categories and treatment options.

Our R&D team observes surgeries and visits clinics to gain real-world insights, and we regularly meet with eye care professionals to get their feedback on our products and their future needs.

Our robust pipeline is complemented by strategic acquisitions and alliances, which accelerate the pace of discovery and delivery of essential eye care innovations. We also support independent researchers and have awarded more than \$22 million in research grants.



CREATING SUSTAINABLE ACCESS TO EYE CARE

Through our social responsibility and advocacy efforts, Alcon helps to create sustainable access to eye care for patients around the world, thereby reducing the incidence of preventable blindness and visual impairment. We work with organizations like Orbis, SEE International, Mercy Ships, Optometry Giving Sight and VisionSpring to help patients in remote areas of the world receive eye exams, much-needed surgeries and access to glasses, as well as help to train doctors and surgeons.

Each year, we give millions of dollars in cash grants, as well as donate products for medical missions that serve more than 400,000 patients in 80 countries. We also provide opportunities for our associates to volunteer their time to serve in our local communities.



SUPPORTING EYE CARE PROFESSIONALS

Our products create possibilities, but it's the many talented and passionate eye care professionals around the world who turn those possibilities into realities. By investing in professional education, we help to advance the eye care industry and ultimately create better outcomes for patients and consumers.

We have more than 60 training centers around the world, and offer a wide variety of training programs for practitioners, students, residents and support staff. And since 2010, we've awarded \$69 million in Independent Medical Education (IME) grants.

References: 1. Scott, Adrienne W., "Public Attitudes About Eye and Vision Health." *JAMA Ophthalmology*. August 04, 2016.
2. 2017 Market Scope Dry Eye Report

© 2018 Novartis 10/18 1809N265

Alcon A Novartis
Division